Because antiparkinsonian drugs available at present do not appear to prevent the progression of PD, clinical applications of c-Abl inhibitors as a future disease-modifying therapeutic strategy for PD have been challenged (Brundin et al., 2013; Lindholm et al., 2016; Pagan et al., 2016; Brahmachari et al., 2017; Lang and Espay, 2018). The gene discussed is ABL1; the disease is Parkinson disease.